Habib Dable has over 30 years of experience in the healthcare industry and is currently an advisor at RA Capital Management, L.P. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., where he led the company through its evolution into a leading rare disease company, including the successful launch of Reblozyl® and eventual sale to Merck in 2021. Prior to that, Mr. Dable held roles of increasing leadership responsibility at Bayer AG for over 20 years, including President of U.S. Pharmaceuticals and Global Head of Specialty Medicine. He is currently an advisor at RA Capital Management and serves on the boards of several biotech companies including Tyra Biosciences, SpyGlass Pharma, Relay Therapeutics, and PepGen and is a former board member of Blueprint Medicines, Day One Biopharmaceuticals, Millendo Therapeutics, Aerovate Therapeutics, and Albireo Pharma. He holds a BBA and MBA from the University of New Brunswick.